Navigation Links
Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
Date:9/3/2007

Ranbaxy will benefit from the 180 day shared exclusivity on the product

PRINCETON, N.J., Aug. 30 /PRNewswire/ -- Ranbaxy Laboratories Limited (RLL), announced today that the Company has received tentative approval from the U.S. Food and Drug Administration to manufacture and market Galantamine Hydrobromide Tablets, 4mg (base), 8mg (base), and 12mg (base). Galantamine is indicated for the treatment of mild to moderate dementia of the Alzheimer's type. Total annual market sales for Razadyne were $130.0 million (IMS - MAT: June 2007).

"This tentative approval will provide Ranbaxy Pharmaceuticals Inc. (RPI) with an opportunity to market this product and anticipate sharing in the period of 180 days exclusivity that will be beneficial to the Company, as well as to the U.S. healthcare system. We will launch the product upon final approval, which is anticipated on December 14, 2008. At the time of launch, product will be available immediately to all classes of trade," according to Jim Meehan, Vice President of Sales and Distribution for RPI.

Ranbaxy Pharmaceuticals Inc. (RPI) based in Jacksonville, Florida, USA, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India's largest pharmaceutical company. RPI is engaged in the sale and distribution of generic and branded prescription products in the U.S. healthcare system.

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, headquartered in India, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies," resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 11 countries.

* Razadyne(TM) is a registered trademark of Janssen Pharmaceutica Inc.

CONTACTS: Charles M. Caprariello

Vice President, Corporate Communications

Ranbaxy Inc.

(609) 720-5615

Edwige Buteau

RF Binder Partners Inc.

(212) 994-7517

Anuj Baveja

RF Binder Partners Inc.

(212) 994-7552


'/>"/>
SOURCE Ranbaxy Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. RANBAXY - enters anti-AIDS segment
2. Ranbaxy joins hand with Cipla to co-market ciprofloxacin
3. Ranbaxy gets US FDA approval for Lisinopril
4. Ranbaxy Labs Entry Into Anti-Acne Market
5. Ranbaxy trying to make inroads in herbal drugs market
6. Lamivudine Manufactured By Ranbaxy gets the nod from the US FDA
7. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
8. Ranbaxy opens Drug discovery centre in Gurgaon
9. Ranbaxy Laboratories All Set To Export Bird Flu Vaccines
10. Ranbaxy Gets USFDA Approval For Doxycycline Tablets
11. SRL Ranbaxy offers quicker bird flu diagnostic test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... 24, 2017 , ... In the Health Care IT campaign, Robert Herjavec discusses ... not if you will be attacked, but when.” However, he and many others involved ... care. , Improvements in auditing and monitoring have taken security in health care a ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... With ProGlass ... Cut Pro X . Users have total control over position, rotation, distortion, edge softness, ... all within Final Cut Pro X. , With ProGlass Prism users are given the ...
(Date:2/24/2017)... ... February 24, 2017 , ... Indiana Fiber Network (IFN) President and ... this year. Dyer started as the Chairman of the Management Committee when IFN ... the corporation including the recruitment of investor/owners and development of the business plan. ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... again hosted their Military Wedding Giveaway, with the winning couple announced on Feb. ... with services generously donated from local vendors: A Matter of Taste, Ryan Rousseau ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through ... return to the La Gorce Country Club in Miami Beach to host its ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... and Markets has announced the addition of the "Global Empty Capsules ... their offering. ... Empty Capsules Market is poised to grow at a CAGR of around ... This industry report analyzes the market estimates and forecasts ... presented in the research scope. The study provides historical market data for ...
(Date:2/24/2017)... Research and Markets has announced the addition of ... report to their offering. ... The latest research Dry eye Drugs Price Analysis and Strategies - 2016, ... The research answers the following questions: ... attributes? How are they positioned in the Global Dry eye market? ...
(Date:2/24/2017)...  In conjunction with DURECT Corporation,s (Nasdaq: ... you are invited to listen to a conference call ... Tuesday, March 14, 2017 at 4:30 pm Eastern Time ... webcast of the presentation will be available by accessing ... Relations."  If you are unable to participate during the ...
Breaking Medicine Technology: